Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and…
<!-- Name:DistributionId Value:8808375 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
BDTX1535
Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of…
- Clinical update expected in second half of 2023 - CAMBRIDGE, Mass. and NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision…
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR…
CAMBRIDGE, Mass. and NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and…
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR…
CAMBRIDGE, Mass. and NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and…